Literature DB >> 12210034

Establishment and characterization of OCUT-1, an undifferentiated thyroid cancer cell line expressing high level of telomerase.

Kana Ogisawa1, Naoyoshi Onoda, Tetsuro Ishikawa, Chiemi Takenaka, Masaaki Inaba, Yoshinari Ogawa, Kosei Hirakawa-Y S Chung.   

Abstract

BACKGROUND &
OBJECTIVES: Undifferentiated thyroid cancer is one of the most aggressive human malignancies, and the prognoses that have been reported are extremely poor. A number of studies have described the clinicopathologic features of this tumor and analyzed its biologic background to explain the extraordinarily aggressive nature of the tumor. Still the mechanism of cellular aggressiveness in undifferentiated thyroid cancer is not yet fully understood.
METHODS: We established and characterized an undifferentiated thyroid cancer cell line, OCUT-1, derived from the surgical specimen obtained from a 74-year-old Japanese woman with advanced undifferentiated thyroid cancer.
RESULTS: The cell line had already maintained over 100 passages and was stably cultured for more than a year. The cell line was observed to maintain not only its morphologic similarity to the primary cancer cells, but also its aggressive nature, including high proliferative activity, numerous genetic abnormalities, and cytokine production. Further, we have demonstrated the expression of telomerase activity in the cell, which could represent one of the responsible mechanisms for the cellular aggressiveness of this type of tumor.
CONCLUSIONS: This cell line might be useful for further study concerning the correlation between telomerase activation and disease progression or anaplastic change in thyroid cancer. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12210034     DOI: 10.1002/jso.10122

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  6 in total

1.  Establishment, characterization and comparison of seven authentic anaplastic thyroid cancer cell lines retaining clinical features of the original tumors.

Authors:  Naoyoshi Onoda; Masanori Nakamura; Naoki Aomatsu; Satoru Noda; Shinichiro Kashiwagi; Kosei Hirakawa
Journal:  World J Surg       Date:  2014-03       Impact factor: 3.352

2.  Methodology, Criteria, and Characterization of Patient-Matched Thyroid Cell Lines and Patient-Derived Tumor Xenografts.

Authors:  Laura A Marlow; Stephen D Rohl; James L Miller; Jeffery A Knauf; James A Fagin; Mabel Ryder; Dragana Milosevic; Brian C Netzel; Stefan K Grebe; Honey V Reddi; Robert C Smallridge; John A Copland
Journal:  J Clin Endocrinol Metab       Date:  2018-09-01       Impact factor: 5.958

3.  Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling pathways.

Authors:  Peng Hou; Ermal Bojdani; Mingzhao Xing
Journal:  J Clin Endocrinol Metab       Date:  2009-12-11       Impact factor: 5.958

4.  Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines.

Authors:  Y Nobuhara; N Onoda; Y Yamashita; M Yamasaki; K Ogisawa; T Takashima; T Ishikawa; K Hirakawa
Journal:  Br J Cancer       Date:  2005-03-28       Impact factor: 7.640

5.  Establishment and characterization of a new human colon cancer cell line, PUMC-CRC1.

Authors:  Xiaocui Bian; Fang Cao; Xiaowan Wang; Yuhong Hou; Haitao Zhao; Yuqin Liu
Journal:  Sci Rep       Date:  2021-06-23       Impact factor: 4.379

6.  Peroxisome proliferator-activated receptor gamma activation induces cell cycle arrest via the p53-independent pathway in human anaplastic thyroid cancer cells.

Authors:  Sung Hwa Chung; Naoyoshi Onoda; Tetsuro Ishikawa; Kana Ogisawa; Chiemi Takenaka; Yoshihisa Yano; Fumihiko Hato; Kosei Hirakawa
Journal:  Jpn J Cancer Res       Date:  2002-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.